Use of long-acting injectable cabotegravir in pregnant and lactating people

Dr. Elaine J. Abrams is a professor of epidemiology and pediatrics at Columbia University and the senior research director at ICAP at Columbia University.

Prof. Nelly R. Mugo is a reproductive health specialist working in Kenya, where she leads a clinical trial site in Thika, Kenya (Partners in Health Research and Development-KEMRI). The majority of her research work is on HIV and cervical cancer prevention with a focus on pre-exposure prophylaxis (PrEP) and HPV vaccines and evaluation of screening and treatment of pre cancer lesions of the cervical.
Together with University of Washington Faculty and Kenya Medical Research Institute scientists she has conducted high impact HIV and cervical cancer prevention research including the Partners PrEP Study, the landmark clinical trial of pre-exposure prophylaxis (PrEP) for HIV prevention among serodiscordant couples and the demonstration project of integrated PrEP and antiretroviral treatment for serodiscordant couples. This work has laid the foundation for PrEP implementation in Kenya and globally. I am a protocol co-chair for the Kenya HPV Single Dose Vaccine study (KEN SHE); the interim results of that trial informed WHO change of recommendations for HPV vaccination for girls

Dr. Elaine J. Abrams is a professor of epidemiology and pediatrics at Columbia University and the senior research director at ICAP at Columbia University.

Prof. Nelly R. Mugo is a reproductive health specialist working in Kenya, where she leads a clinical trial site in Thika, Kenya (Partners in Health Research and Development-KEMRI). The majority of her research work is on HIV and cervical cancer prevention with a focus on pre-exposure prophylaxis (PrEP) and HPV vaccines and evaluation of screening and treatment of pre cancer lesions of the cervical.
Together with University of Washington Faculty and Kenya Medical Research Institute scientists she has conducted high impact HIV and cervical cancer prevention research including the Partners PrEP Study, the landmark clinical trial of pre-exposure prophylaxis (PrEP) for HIV prevention among serodiscordant couples and the demonstration project of integrated PrEP and antiretroviral treatment for serodiscordant couples. This work has laid the foundation for PrEP implementation in Kenya and globally. I am a protocol co-chair for the Kenya HPV Single Dose Vaccine study (KEN SHE); the interim results of that trial informed WHO change of recommendations for HPV vaccination for girls

Sinead Delany-Moretlwe, MBBCh PhD DTM&H is Director: Research at Wits RHI and Professor of Global Health and Infectious Diseases at the University of the Witwatersrand, Johannesburg. Her research interests span the intersections between sexual and reproductive health (SRH) and infectious diseases. She has been an investigator on several phase III trials of new HIV prevention technologies, and led the phase III trial of cabotegravir as injectable PrEP for women. She has led several studies investigating approaches to HPV screening and vaccination in people living with HIV, as well as trials of new treatments and vaccines for gonorrhoea. She an advisor on several South African and WHO advisory committees.

Dr. Mark Marzinke is a Professor of Pathology and Medicine (Clinical Pharmacology) at the Johns Hopkins University School of Medicine. He is Co-Principal Investigator of the HIV Prevention Trials Network Laboratory Center, and has expertise in analytical and anti-infective pharmacology.

Imelda Chipo Mahaka is the Executive Director for Pangaea Zimbabwe in Harare, Zimbabwe, providing programmatic and operational oversight to the organization. She has been involved in policy advocacy, socio-behavioral research, community engagement, and service delivery around HIV prevention, treatment, and support. She has over 15 years of experience in managing and coordinating programs, and training, including experience in the development of training manuals and curricula with content on HIV/AIDS for adolescents and adapting public health intervention models to be more culturally appropriate for low resourced communities. More recently, her work has branched into product introduction and scale advocating for more options and choice for women, AGYW and key populations. Formerly with the UZ-UCSF Women’s Research Programme and Zimbabwe AIDS Prevention Project, Imelda has extensive experience in Socio behavioural research in HIV/AIDS and SRH especially working with adolescents and has expanded more recently to Implementation science around HIV prevention. Imelda is a certified social worker, project manager, and researcher, passionate about working with and contributing to improved health outcomes for adolescents, women, and other priority population groups. An avid activist, she is a member of AfroCAB working towards empowered communities. She also sits on several study trials committees representing communities (LEAP, EMPIRICAL, BREATHER-PLUS) and sits on the WHO ART, COVID, and Sepsis Guidelines Development Groups.

Dr. Elaine J. Abrams is a professor of epidemiology and pediatrics at Columbia University and the senior research director at ICAP at Columbia University.

Prof. Nelly R. Mugo is a reproductive health specialist working in Kenya, where she leads a clinical trial site in Thika, Kenya (Partners in Health Research and Development-KEMRI). The majority of her research work is on HIV and cervical cancer prevention with a focus on pre-exposure prophylaxis (PrEP) and HPV vaccines and evaluation of screening and treatment of pre cancer lesions of the cervical.
Together with University of Washington Faculty and Kenya Medical Research Institute scientists she has conducted high impact HIV and cervical cancer prevention research including the Partners PrEP Study, the landmark clinical trial of pre-exposure prophylaxis (PrEP) for HIV prevention among serodiscordant couples and the demonstration project of integrated PrEP and antiretroviral treatment for serodiscordant couples. This work has laid the foundation for PrEP implementation in Kenya and globally. I am a protocol co-chair for the Kenya HPV Single Dose Vaccine study (KEN SHE); the interim results of that trial informed WHO change of recommendations for HPV vaccination for girls

Sinead Delany-Moretlwe, MBBCh PhD DTM&H is Director: Research at Wits RHI and Professor of Global Health and Infectious Diseases at the University of the Witwatersrand, Johannesburg. Her research interests span the intersections between sexual and reproductive health (SRH) and infectious diseases. She has been an investigator on several phase III trials of new HIV prevention technologies, and led the phase III trial of cabotegravir as injectable PrEP for women. She has led several studies investigating approaches to HPV screening and vaccination in people living with HIV, as well as trials of new treatments and vaccines for gonorrhoea. She an advisor on several South African and WHO advisory committees.

Dr. Mark Marzinke is a Professor of Pathology and Medicine (Clinical Pharmacology) at the Johns Hopkins University School of Medicine. He is Co-Principal Investigator of the HIV Prevention Trials Network Laboratory Center, and has expertise in analytical and anti-infective pharmacology.

Imelda Chipo Mahaka is the Executive Director for Pangaea Zimbabwe in Harare, Zimbabwe, providing programmatic and operational oversight to the organization. She has been involved in policy advocacy, socio-behavioral research, community engagement, and service delivery around HIV prevention, treatment, and support. She has over 15 years of experience in managing and coordinating programs, and training, including experience in the development of training manuals and curricula with content on HIV/AIDS for adolescents and adapting public health intervention models to be more culturally appropriate for low resourced communities. More recently, her work has branched into product introduction and scale advocating for more options and choice for women, AGYW and key populations. Formerly with the UZ-UCSF Women’s Research Programme and Zimbabwe AIDS Prevention Project, Imelda has extensive experience in Socio behavioural research in HIV/AIDS and SRH especially working with adolescents and has expanded more recently to Implementation science around HIV prevention. Imelda is a certified social worker, project manager, and researcher, passionate about working with and contributing to improved health outcomes for adolescents, women, and other priority population groups. An avid activist, she is a member of AfroCAB working towards empowered communities. She also sits on several study trials committees representing communities (LEAP, EMPIRICAL, BREATHER-PLUS) and sits on the WHO ART, COVID, and Sepsis Guidelines Development Groups.